Stanley Durrleman is an Inria research director and head of the Aramis team at the Paris Brain Institute (ICM). His research has led him to build personalized models of disease progression, notably in Alzheimer's, Parkinson's and Huntington's diseases. These models are used to determine the optimum time to test new therapies in individual patients, and are helping to change the way clinical trials are conducted.
Stanley Durrleman has received several prestigious scientific awards, including the second Gilles Kahn Award for the best thesis in computer science in 2010, and an ERC Starting Grant from the European Research Council in 2015. In 2019, he was the first winner of a Sanofi iDEA award outside the United States. In 2020, he received the Inria - Académie des sciences young researcher award.
In 2022, he co-founded the start-up Qairnel, and a few months later launched docteurmemo.fr, the first digital clinic dedicated to memory disorders.
